Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence

Exclusion Criteria

• •1. Meets DSM IV criteria for current major depression, bipolar disorder, schizophrenia, any psychotic illness, including substance-induced psychosis, and current substance-induced mood disorder with HAMD \> 12.
• •2. Physiological dependence on another substance requiring medical management, such as alcohol or benzodiazepines, excluding caffeine, nicotine, and cannabis
• •3. Pregnant or interested in becoming pregnant
• •4. Delirium, Dementia, Amnesia, Cognitive Disorders, or dissociative disorders
• •5. Current suicide risk or a history of suicide attempt within the past 2 years
• •6. On psychotropic or other medication whose effect could be disrupted by participation in the study
• •7. Recent history of significant violence (past 2 years).
• •8. Heart disease as indicated by history, abnormal ECG, previous cardiac surgery.
• •9. Unstable physical disorders which might make participation hazardous such as end-stage AIDS, hypertension (\>140/90), anemia, active hepatitis or other liver disease (transaminase levels \< 2 X the upper limit of normal will be considered acceptable), or untreated diabetes
• •10. Previous history of CI-581 abuse, and/or a history of adverse reaction/experience wtih prior exposure to CI-581 or benzodiazepines
• •11. BMI \> 35, or a history of unmanaged obstructive sleep apnea
• •12. First degree relative with a psychotic disorder (bipolar disorder with psychotic features, schizophrenia, schizoaffective disorder, or psychosis NOS)
• •13. History of opioid overdose over the past 2 years requiring medical intervention
• •14. Currently using methadone or buprenorphine